Opium (Opioid) Addiction - Pipeline Review, H2 2017

Date: September 12, 2017
Pages: 114
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O44D6D3C48BEN
Leaflet:

Download PDF Leaflet

Opium (Opioid) Addiction - Pipeline Review, H2 2017
Opium (Opioid) Addiction - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2017, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 7, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Opium (Opioid) Addiction - Overview
Opium (Opioid) Addiction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Opium (Opioid) Addiction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
Alkermes Plc
Aoxing Pharmaceutical Company Inc
BioCorRx Inc
BioDelivery Sciences International Inc
Camurus AB
Fab'entech SA
Foresee Pharmaceuticals LLC
Indivior Plc
Insys Therapeutics Inc
iX Biopharma Ltd
Nemus Bioscience Inc
Novartis AG
Omeros Corp
Opiant Pharmaceuticals Inc
Orexigen Therapeutics Inc
Orexo AB
Pfizer Inc
Relmada Therapeutics Inc
Teva Pharmaceutical Industries Ltd
Titan Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc
Opium (Opioid) Addiction - Drug Profiles
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
18-MC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANS-6637 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody for Poisoning, Drug Overdose and Opioid Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQU-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride depot - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buprenorphine MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Canquit-O - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FP-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mavoglurant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-2111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-2222 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NT-814 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OREX-1019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-4363467 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-5006739 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize D3 Receptor for Opioid Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEV-90109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Opioid Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Opium Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Opium (Opioid) Addiction - Dormant Projects
Opium (Opioid) Addiction - Discontinued Products
Opium (Opioid) Addiction - Product Development Milestones
Featured News & Press Releases
Sep 01, 2017: Indivior Responds To Court Rulings in ANDA Litigation and Announces Intention To Appeal
Aug 02, 2017: Zubsolv gains preferred position on CVS Caremark 2018 Formulary
Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
Jul 31, 2017: Indivior Announces FDA Acceptance with Priority Review Designation of RBP-6000 Buprenorphine Monthly Depot New Drug Application (NDA) for the Treatment of Opioid Use Disorder
Jul 25, 2017: BioCorRx Announces EnLite Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio
Jul 20, 2017: Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder
Jul 10, 2017: Orexigen Announces Presentation of Data for OREX-1019, Candidate for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction
Jul 06, 2017: BioCorRx to Exhibit at ASAM Conference in Dallas, Texas
Jun 29, 2017: Fortune Article Highlights Titan Pharmaceuticals And Its ProNeura Technology
Jun 29, 2017: Indivior Provides Update on RBP-6000
Jun 22, 2017: Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms
Jun 21, 2017: Indivior Presents Results from the Phase 3 Pivotal Study of RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder
Jun 15, 2017: Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine
Jun 13, 2017: Braeburn and Knight Therapeutics Announce Filing of PROBUPHINE in Canada
Jun 06, 2017: TSRI Anti-Heroin Vaccine Found Effective in Non-Human Primates
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Opium (Opioid) Addiction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2017
Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017
Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H2 2017
Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc, H2 2017
Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2017
Opium (Opioid) Addiction - Pipeline by Fab'entech SA, H2 2017
Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals LLC, H2 2017
Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2017
Opium (Opioid) Addiction - Pipeline by Insys Therapeutics Inc, H2 2017
Opium (Opioid) Addiction - Pipeline by iX Biopharma Ltd, H2 2017
Opium (Opioid) Addiction - Pipeline by Nemus Bioscience Inc, H2 2017
Opium (Opioid) Addiction - Pipeline by Novartis AG, H2 2017
Opium (Opioid) Addiction - Pipeline by Omeros Corp, H2 2017
Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2017
Opium (Opioid) Addiction - Pipeline by Orexigen Therapeutics Inc, H2 2017
Opium (Opioid) Addiction - Pipeline by Orexo AB, H2 2017
Opium (Opioid) Addiction - Pipeline by Pfizer Inc, H2 2017
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics Inc, H2 2017
Opium (Opioid) Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, H2 2017
Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
Opium (Opioid) Addiction - Dormant Projects, H2 2017
Opium (Opioid) Addiction - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Opium (Opioid) Addiction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Alkermes Plc
Aoxing Pharmaceutical Company Inc
BioCorRx Inc
BioDelivery Sciences International Inc
Camurus AB
Fab'entech SA
Foresee Pharmaceuticals LLC
Indivior Plc
Insys Therapeutics Inc
iX Biopharma Ltd
Nemus Bioscience Inc
Novartis AG
Omeros Corp
Opiant Pharmaceuticals Inc
Orexigen Therapeutics Inc
Orexo AB
Pfizer Inc
Relmada Therapeutics Inc
Teva Pharmaceutical Industries Ltd
Titan Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc
Skip to top


Alcohol Addiction - Pipeline Review, H2 2017 US$ 2,000.00 Jul, 2017 · 132 pages

Ask Your Question

Opium (Opioid) Addiction - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: